Siamak Daneshmand, MD, on next steps with TAR-200 in NMIBC - Urology Times
Siamak Daneshmand, MD, discusses TAR-200's safety, tolerability, and high complete response rates (85%) in NMIBC patients from the SunRISe-1 trial. He highlights the psychological benefits of a continuous drug release system and future potential for combination therapies.
Highlighted Terms
Related News
Siamak Daneshmand, MD, on next steps with TAR-200 in NMIBC - Urology Times
Siamak Daneshmand, MD, discusses TAR-200's safety, tolerability, and high complete response rates (85%) in NMIBC patients from the SunRISe-1 trial. He highlights the psychological benefits of a continuous drug release system and future potential for combination therapies.